>
Adalta logo

1AD - Adalta Share Price

A$0.165 0.0  0.0%

Last Trade - 6:04am

Sector
Healthcare
Size
Micro Cap
Market Cap £22.7m
Enterprise Value £18.2m
Revenue £2.39m
Position in Universe 1230th / 1898
Bullish
Bearish
Unlock 1AD Revenue
Momentum
Relative Strength (%)
1m -14.2%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -37.7%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Jun 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.88 0.75 1.97 2.08 3.59 3.85 3.24 3.28 +34.2%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 31 December 2020, AdaltaLtd revenues increased 100% to A$807K. Net loss decreased25% to A$4.5M. Revenues reflect R&D Tax incentives increasefrom A$205K to A$624K. Lower net loss reflects Research anddevelopment expenses decrease of 25% to A$3.7M (expense),Selling/General/Admin. Expense decrease of 4% to A$1.1M(expense), Share based payment expenses decrease of 5% toA$278K (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

1AD Revenue Unlock 1AD Revenue

Net Income

1AD Net Income Unlock 1AD Revenue

Normalised EPS

1AD Normalised EPS Unlock 1AD Revenue

PE Ratio Range

1AD PE Ratio Range Unlock 1AD Revenue

Dividend Yield Range

1AD Dividend Yield Range Unlock 1AD Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
1AD EPS Forecasts Unlock 1AD Revenue
Profile Summary

AdAlta Limited is an Australia-based drug discovery and development company. The Company is focused on using its technology platform to generate protein therapeutics, known as i-bodies, for treating a range of human diseases. The Company's principal activity is to develop its ibody platform with a focus on its lead candidate AD-114, a treatment for idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases. Its i-body AD-114 drug candidate is used for treatment in various fibrosis related eye diseases to support the pre-clinical development of the eye fibrosis indication. The Company's AD-114 has shown both anti-fibrotic and anti-inflammatory effects in various animal models. The Company's AD-114 is used in various therapeutic applications for fibrosis diseases of the liver, skin, kidney and heart. AD-114 has completed pre-clinical studies in vitro (in the lab) and in vivo (in animals) data obtained.

Directors
Last Annual June 30th, 2020
Last Interim December 31st, 2020
Incorporated June 22, 2006
Public Since August 22, 2016
No. of Shareholders: 1,100
No. of Employees: n/a
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange Australian Stock Exchange - SEATS
Shares in Issue 245,175,853
Free Float (0.0%)
Eligible for
ISAs
SIPPs
1AD Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for 1AD
Upcoming Events for 1AD
Frequently Asked Questions for Adalta
What is the Adalta share price?

As of 6:04am, shares in Adalta are trading at A$0.165, giving the company a market capitalisation of £22.7m. This share price information is delayed by 15 minutes.

How has the Adalta share price performed this year?

Shares in Adalta are currently trading at A$0.165 and the price has moved by 0.287k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Adalta price has moved by 0.189k% over the past year.

What are the analyst and broker recommendations for Adalta?

There are no analysts currently covering Adalta.

When will Adalta next release its financial results?

Adalta is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Adalta dividend yield?

Adalta does not currently pay a dividend.

Does Adalta pay a dividend?

Adalta does not currently pay a dividend.

When does Adalta next pay dividends?

Adalta does not currently pay a dividend.

How do I buy Adalta shares?

To buy shares in Adalta you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Adalta?

Shares in Adalta are currently trading at A$0.165, giving the company a market capitalisation of £22.7m.

Where are Adalta shares listed? Where are Adalta shares listed?

Here are the trading details for Adalta:

Country of listing: Australia
Exchange: ASX
Ticker Symbol: 1AD
What kind of share is Adalta?

Based on an overall assessment of its quality, value and momentum, Adalta is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Adalta share price forecast 2021?

Shares in Adalta are currently priced at A$0.165. At that level they are trading at 9.09% discount to the analyst consensus target price of 0.00.

Analysts covering Adalta currently have a consensus Earnings Per Share (EPS) forecast of -0.02 for the next financial year.

How can I tell whether the Adalta share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Adalta. Over the past six months, the relative strength of its shares against the market has been 3.54%. At the current price of A$0.165, shares in Adalta are trading at 27.17% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Adalta PE Ratio?

We were not able to find PE ratio data for Adalta.

Who are the key directors of Adalta?

Adalta's management team is headed by:

Elizabeth McCall - DRC
Michael Foley - CSO
Kate Griffiths - OTH
James Williams - DRC
Robert Peach - NED
Cameron Jones - SEC
Dallas Hartman - COO
Rosalind Wilson - NED
Paul MacLeman - CHM
Timothy Oldham - CEO
David Fuller - NED
Who are the major shareholders of Adalta?

Here are the top five shareholders of Adalta based on the size of their shareholding:

Yuuwa Capital LP Venture Capital
Percentage owned: 22.05% (54.1m shares)
Platinum Investment Management Ltd. Investment Advisor/Hedge Fund
Percentage owned: 10.2% (25.0m shares)
Meurs Holdings Pty. Ltd. Corporation
Percentage owned: 7.28% (17.9m shares)
Knight61 Investments Pty. Ltd. Corporation
Percentage owned: 1.71% (4.20m shares)
CityCastle Pty. Ltd. Corporation
Percentage owned: 1.4% (3.44m shares)
Similar to 1AD
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.